Clinical Trial Update: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase I/II autologous engineered TCR T-cell therapy trial for advanced pancreatic ductal adenocarcinoma, non-small cell lung cancer, and colorectal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells

Snippet

Sponsor: Affini-T Therapeutics, Inc. | Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING